Capecitabine Market: Industry Analysis and Forecast 2023-202: By size

Capecitabine Market is anticipated to reach US$ 2.99 Bn by 2029 from US$ 0.61 Bn in 2022 at a CAGR of 6.2 % during a forecast period. Capecitabine is a prodrug that operates as a nucleoside metabolic inhibitor. The chemical is transformed into fluorouracil, which inhibits DNA synthesis and slows cancer cell development. It's taken orally and is authorized to treat a variety of tumors, including metastatic colorectal cancer, breast cancer, and others.